Abstract: The subject of the invention is a water-soluble macromolecular conjugate of hemoglobin characterized in that it is constitutedon the one hand, by hemoglobin,on the other, by a water-soluble polymer P containing polar groups, this macromolecular conjugate contains Z sites, bound to the polymer P and containing at least one negative charge carried for example by sulfate groups, the polymer P being bound to hemoglobinon the one hand, through the intermediary of at least one linkage established between at least one of the Z sites contained in the polymer and hemoglobin,and, on the other, through the intermediary of at least one covalent linkage established between the polymer and hemoglobin, or between at least one of the Z sites contained in the polymer and hemoglobin.The macromolecular conjugates according to the invention exhibit a lower affinity for oxygen than that of free hemoglobin.

Abstract: Immunoglobulin M is purified by absorption upon an insoluble matrix material having chemically bound thereon the protein C1q. The matrix is washed and purified immunoglobulin M is then released from the matrix.

Abstract: The present invention relates to a process for preparing peptide synthons in which the optical purity of each of the peptides to be condensed is retained.According to this process, a silyl derivative of an amino acid or peptide, which is activated by a complex chloroimmonium salt, a complex coordinated phosphorus halide, oxyhalide salt or a complex oxalyl halide salt, is prepared. The activated peptide is then condensed with an N-silyl amino acid or peptide in which the acid group is protected.

Abstract: Active recombinant human IL-4 is purified from a crude fermentation broth of a secreted E. coli mutant by subjecting said solution to selective chromatogrphy on a zinc-chelating agarose column at pH 7.2 in a buffer containing a high concentration of sodium chloride, i.e., about 1M sodium chloride, washing first with a phosphate buffer at pH 7.2 containing 1.0M sodium chloride then with a buffer containing 10% glycerol and eluting at pH 5.0. The resulting purified active recombinant human IL-4 solution is further treated by cation exchange chromatography, concentration by diafiltration up to 20 mg/mL and size exclusion gel chromatography using a citrate buffer at pH 4.5.

Abstract: A process for producing .kappa.-casein glycomacropeptides which comprises adjusting the pH of a solution of milk starting materials containing the .kappa.-casein glycomacropeptides to below 4, treating the solution by ultrafiltration with a membrane having a fraction molecular weight of 10,000-50,000, and concentrating the obtained filtrate with a membrane having a fraction molecular weight of 50,000 or less.

Abstract: Process for the preparation of an immunoglobulin solution suitable for intravenous administration from a human blood protein fraction containing immunoglobulins IgG, IgA and IgM in partially concentrated from, with the process steps: addition of acetate buffer to the protein fraction, where appropriate removal of insoluble constituents by filtration, treatment with calcium phosphate and octanoic acid, centrifugation, removal of the supernatant and treatment thereof with an adsorbent, removal of the adsorbent and sterilization by filtration.

Abstract: A novel hyposensitization agent was prepared by covalently attaching a saccharide to a cedar pollen allergen having a partial amino acid sequence of Ala-Ile-Asn-Ile-Phe-Asn- beginning at its N-terminal. The hyposensitization agent, when compared with an intact cedar pollen allergen, extremely accelerates the production of immunoglobulin G and M antibodies which are specific to intact cedar pollen allergen, but extremely reduces the production of immunoglobulin E antibody which is specific to the allergen. Thus, the hyposensitization agent is administrable to cedar pollinosis patients with no anaphylaxis and allergy, and cuts hyposensitization period to about 1/3 to 1/200.

Abstract: The invention relates to a polymeric anhydride of magnesium and proteic ammonium phospholinoleate having the following distribution of components expressed in percentage of magnesium (20.1.+-.0.9%), Ammonium (10.0.+-.3.3%), Phosphate (45.2.+-.2.7%), linoleic acid (11.6.+-.4.3%), total protein (0.49.+-.0.07%) with the presence in percentage of the following aminoacids: Aspartic Acid (7.19%), Threonine (3.56%), Serine (7.56%), Glutamic Acid (8.53%), Proline (0.5%), Glycine (9.69%), Alanine (7.46%), Valine (1.0%), Methionine (4.38%), Isoleucine (2.54%), Leucine (3.03%), Thyrosine (0.5%), Phenylanine (1.0%), Histidine (2.83%), Lysine (3.56%), Tryptofan (1.3%) and Arginine (35.2%).This compound is produced from a selected line of Aspergillus sp in culture of oat schaff and bouillon at the temperature of 30.degree./35.degree. C., pH 3-4 with low aeration (10 l/m) and agitation (40 rph) restricted to the first 48 hours of the producing process.

Abstract: The present invention relates to a new method for increasing the productivity of sows.In the method according to the invention, Bacillus IP 5832 and/or its spores is/are administered orally to breeding sows.

Abstract: A type II, proteinaceous, antigenic factor derived from a Group A streptococci which is a receptor for the Fc region of human Ig G3 and which exhibits a major diffuse protein band on polyacrylamide gel electrophoresis and which has a molecular weight of about 38,000 daltons.

Abstract: A pharmaceutical composition and method are provided for erythropoietin therapy, such as treatment of an anemic disease, wherein an effective amount of activin with two beta.sub.B chains formulated in a pharmaceutically acceptable carrier is administered to a patient or animal in need of such therapy. Preferably the activin is human and the composition is administered parenterally.

Abstract: High molecular weight protein/fatty acid condensation products obtained by reaction of one mole of a protein hydrolysate of average molecular mass 3,000 to 7,000 with 0.5 to 3, preferably 2 to 2.5, moles of a C.sub.12 -C.sub.18 -fatty acid chloride in aqueous medium at a pH of 7 to 12. These protein/fatty acid condensation products are distinguished by eliciting no mucosal irritation whatever. They are therefore outstandingly suitable as surfactants for mild washing and cleansing agents.

Abstract: A novel peptide possessing excellent antihypertensive activity is disclosed. The peptide has the formula:Pro-Thr-His-Ile-Lys-Trp-Gly-Asp (I)and can be prepared by purifying a fluid extracted from fish tissues or by combining constituting amino acids by a peptide synthesis method. It exhibits excellent ACE inhibitory activity, low toxicity, and good stability, and is thus an extremely useful and effective antihypertensive substance.

Abstract: The present invention provides acylated epidermal growth factor derivatives, methods of making the derivatives and pharmaceutical compositions containing the derivatives.

Abstract: Insulin preparations with improved properties for parenteral administration can be prepared at pH values of about 3 to 8.5 by presence of magnesium ions in concentration of about 0.005 to 0.5M, a preferred range is 0.02M to 0.5M.

Abstract: Therapeutic treatment of malignant melanoma in humans is disclosed wherein a synergistically effective amount of DTIC in combination with IL-2 is administered to an individual having such cancer.

Abstract: Whey derived from ordinary milk includes a bottom fraction including lactose and minerals, a middle fraction including lower molecular weight proteins, and a top fraction including higher molecular weight proteins. The top whey fraction includes a measurable but low level concentration of immunologically active immunoglobulin plus other pathogen specific antibodies. The whey is ultrafiltered through one or more different process steps to yield a filtered product having a concentration of immunologically active immunoglobulin of at least about seven percent of total solids. The filtered product is periodically tested to verify its activity to a specified microbe. The filtered product is orally administered in a therapeutically effective dose to an animal to treat a disease.

Abstract: Methodology is described for the carboxyl-terminal sequencing of proteins and peptides using novel coupling reagents.

Abstract: A novel and convenient process is described for providing protected amino acids and activating agents for solid phase synthesis which drastically reduces the capital costs of equipment required for the preparation of peptides. The two normally very reactive reagents, when mixed as anhydrous powders are shelf stable and yet form an active compound rapidly when mixed together in solution. This invention presents a method for combining these highly reactive dry solids in a manner which makes them unreactive and shelf stable at room temperature for extended periods of time. Once the solids are dissolved in solvent, a highly reactive amino acid ester that can readily be used in solid phase peptide synthesis is formed. This method of delivery of reagents to an automated peptide synthesizer allowers a very simplified instrument to be constructed using fewer and less expensive components and significantly reducing the associated software required.

Abstract: The present invention relates to methods of treating mental disorders and memory deficits not caused by HIV infection. The methods involve administration of a thymoleptic effective amount of defined linear peptides to patients. The peptides can be administered for example, as a powder or a solution obtained by dissolving a powder in a pharmaceutically acceptable solvent.